Johnson & Johnson's new drug TECVAYLI® shows promise in treating multiple myeloma with no severe side effects.

Johnson & Johnson's new drug TECVAYLI® shows promise as a frontline treatment for newly diagnosed multiple myeloma patients. In studies, all patients achieved minimal residual disease (MRD) negativity and maintained it throughout the treatment. The drug was generally well-tolerated, though some common side effects included infections and low blood cell counts. No severe adverse events led to discontinuation or death.

December 08, 2024
7 Articles

Further Reading